GLOW and SPOTLIGHT: enlightening evidence for the treatment of gastric cancers reported

The findings of two recent clinical trial studies, SPOTLIGHT and GLOW, show promising results for the treatment of specific gastric cancers. The full results of both of these trials were recently presented during the March 2023 session of the ASCO Plenary Series. Currently, there is not a recommended specific regimen that is used in clinical practice for the treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. To account for this, standard approved chemotherapy regimens were selected in combination with zolbetuximab: CAPOX in the GLOW trial and mFOLFOX6 in the SPOTLIGHT trial. Zolbetuximab is a monoclonal...